Abstract
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) first appeared in China in December 2019 and since then, the outbreak expanded globally. Due to the limited supply of SARS-CoV-2 medicines on the market, an immediate strategy was required to accelerate the development of new drugs. Drug repurposing is one of the novel approaches for the therapeutics of several life-threatening diseases. This study identified 408 SARS-CoV-2-associated SNPs from the Genome-Wide Association Study (GWAS) catalog and 391 risk genes associated with SARS-CoV-2. The prioritization was performed based on six categories of functional annotations. SARS-CoV-2 risk genes were mapped into an expanded PPI network using the STRING database. We discovered the drugs that target deregulate SARS-CoV-2 risk genes. Here, we demonstrated the drug target genes overlapped with the drugs for other clinical indications. Hence, we suggest that the identified drugs may be repurposed for the treatment of SARS-CoV-2 and its variants. Overall, this study emphasizes the integration of functional genomic variants and bioinformatics-based approaches to drive drug repurposing efforts for the therapeutics options for COVID-19.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
